Marcin Kortylewski is an associate professor in the Department of Immuno-Oncology at City of Hope Cancer Center. Since 2010, his laboratory has focused on molecular mechanisms of cancer resistance to treatment. Marcin is an inventor of a novel cancer immunotherapy using targeted oligonucleotide delivery to the tumor microenvironment to inhibit or knock down STAT3 protein, a master brake of immune cell activity. He recently co-founded iSTAT Therapeutics Inc., a company that plans to bring the first oligonucleotide STAT3 inhibitor to clinical testing in cancer immunotherapy in 2020. He is joined by team members Daniel Rossi and Alvin Zhang.